87 related articles for article (PubMed ID: 6542371)
1. Postsurgical adjuvant treatment of malignant melanoma patients by the thymic factor thymostimulin.
Azizi E; Brenner HJ; Shoham J
Arzneimittelforschung; 1984; 34(9):1043-7. PubMed ID: 6542371
[TBL] [Abstract][Full Text] [Related]
2. [Survival analysis in patients with cutaneous malignant melanoma].
Radović-Kovacević V; Pekmezović T; Adanja B; Jarebinski M; Marinković J; Tomin R
Srp Arh Celok Lek; 1997; 125(5-6):132-7. PubMed ID: 9265233
[TBL] [Abstract][Full Text] [Related]
3. The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
McClay EF; McClay ME; Monroe L; Baron PL; Cole DJ; O'Brien PH; Metcalf JS; Maize JC
Br J Cancer; 2000 Jul; 83(1):16-21. PubMed ID: 10883662
[TBL] [Abstract][Full Text] [Related]
4. [Therapy and prognosis of malignant melanoma of the skin].
Braun-Falco O; Landthaler M; Hölzel D; Konz B; Schmoeckel C
Dtsch Med Wochenschr; 1986 Nov; 111(46):1750-6. PubMed ID: 3780438
[TBL] [Abstract][Full Text] [Related]
5. A retrospective observational study of primary cutaneous malignant melanoma patients treated with excision only compared with excision biopsy followed by wider local excision.
McKenna DB; Lee RJ; Prescott RJ; Doherty VR
Br J Dermatol; 2004 Mar; 150(3):523-30. PubMed ID: 15030337
[TBL] [Abstract][Full Text] [Related]
6. [Adjuvant chemotherapy of malignant melanoma with DTIC. Lack of effect in stage I. Possible improvement of the prognosis for survival in stage IIb].
Garbe C; Guenther-Eymann K; Stadler R; Orfanos CE
Hautarzt; 1988 Apr; 39(4):205-12. PubMed ID: 3384660
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
[TBL] [Abstract][Full Text] [Related]
8. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
Kretschmer L; Helmbold P; Emmert S; Marsch WC
Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468
[TBL] [Abstract][Full Text] [Related]
9. [Adjuvant therapy of primary malignant melanoma with natural human interferon-beta. Significant survival advantage in 96 treated patients in comparison with 288 untreated symptomatic controls].
Beiteke U; Ruppert P; Garbe C; Oxenfarth R; Kastl I; Türker T; Tronnier H; Frosch PJ
Hautarzt; 1993 Jun; 44(6):365-71. PubMed ID: 8335459
[TBL] [Abstract][Full Text] [Related]
10. [Multidisciplinary treatment of malignant melanoma].
Ikeda S; Esumi H; Suzuki T; Tomita Y
Gan No Rinsho; 1985 Jul; 31(9 Suppl):1079-87. PubMed ID: 4057572
[TBL] [Abstract][Full Text] [Related]
11. Prognostic scoring in patients with melanoma after adjuvant isolated limb perfusion.
Nagabhúshan JS; Murphy K; Angerson W; Kingsmore DB; Byrne DS; McKay AJ
J Surg Res; 2007 Mar; 138(1):22-4. PubMed ID: 17174339
[TBL] [Abstract][Full Text] [Related]
12. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
[TBL] [Abstract][Full Text] [Related]
13. [Adjuvant chemotherapy as a component of complex treatment for skin melanoma].
Kudriavtsev DV; Kudriavtseva GT; Mardynskiĭ IuS
Vopr Onkol; 2008; 54(2):170-7. PubMed ID: 18522165
[TBL] [Abstract][Full Text] [Related]
14. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
Agarwala SS; Neuberg D; Park Y; Kirkwood JM
Cancer; 2004 Apr; 100(8):1692-8. PubMed ID: 15073858
[TBL] [Abstract][Full Text] [Related]
15. [Value of regional lymph node excision for prognosis of advanced malignant melanoma treated by perfusion of the extremity].
Huber R; Krüger I; Stützer H
Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():118-21. PubMed ID: 9101808
[TBL] [Abstract][Full Text] [Related]
16. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma.
Spitler LE; Weber RW; Allen RE; Meyer J; Cruickshank S; Garbe E; Lin HY; Soong SJ
J Immunother; 2009; 32(6):632-7. PubMed ID: 19483646
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group.
Eigentler TK; Radny P; Hauschild A; Gutzmer R; Linse R; Pföhler C; Wagner SN; Schadendorf D; Ellwanger U; Garbe C;
Melanoma Res; 2008 Oct; 18(5):353-8. PubMed ID: 18781134
[TBL] [Abstract][Full Text] [Related]
18. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma.
Nowecki ZI; Rutkowski P; Nasierowska-Guttmejer A; Ruka W
Ann Surg Oncol; 2006 Dec; 13(12):1655-63. PubMed ID: 17016755
[TBL] [Abstract][Full Text] [Related]
19. [Clinical results of extremity perfusion in malignant melanoma].
Huber R; Stützer H; Krüger I
Zentralbl Chir; 1996; 121(3):234-42. PubMed ID: 8867351
[TBL] [Abstract][Full Text] [Related]
20. [Surgical treatment and regional chemotherapy in melanoma of the extremities].
Henneking K; Binder J; Weyers W; Schwemmle K
Chirurg; 1993 Feb; 64(2):134-8. PubMed ID: 8462350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
